Medicenna Therapeutics Corp is seeing a notable increase in its stock price, catching the attention of investors.
Today, Medicenna Therapeutics Corp (MDNA.TO) shares are up by 5.00%, closing at CA$0.42. This rise comes as the company makes progress in its clinical developments and public offerings.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$36.92M
52W high
$1.97
52W low
$0.34
1W change
+2.56%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 700.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+700.0% Upside
Current Price
C$0.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
68.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.43 |
| 60 trading days | C$0.36 | C$0.29 – C$0.43 |
| 90 trading days | C$0.33 | C$0.26 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Medicenna’s ongoing clinical trials and any announcements about public offerings, as these could significantly affect future stock performance.
Medicenna's Market Cap Reaches CA$36.9 Million
With a market cap of CA$36.9 million, Medicenna is a small-cap player in the biotech sector. This often means higher risk but also the potential for greater rewards for investors.
Bull case
The recent stock price increase may indicate growing confidence among investors in Medicenna's clinical trials and its ability to secure funding through public offerings.
Bear case
Despite the positive trend, investors should stay cautious. The biotech sector can be unpredictable, and the absence of recent news might lead to uncertainty.
Recent Performance
Advertisement
Medicenna Therapeutics Corp has seen a 5.00% increase in its shares today. This is significant for a company with a market cap of CA$36.9 million, suggesting a positive sentiment among investors.
Market Reactions
Today's stock performance may be driven by investor optimism surrounding Medicenna's ongoing clinical trials and recent public offerings. As the company continues to develop its pipeline, market reactions could remain volatile.
Looking Ahead
As Medicenna Therapeutics Corp moves forward, investors should watch for new developments regarding its clinical trials and public offerings. These factors could play a crucial role in shaping the stock's future trajectory.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
